Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 2/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | GABRP | O00591 | 1/20 | 0.41 |
| ▸ | GABRD | O14764 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.41 |
| ▸ | GABRE | P78334 | 1/20 | 0.41 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.41 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.41 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.41 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 11/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29607952 | 1.00 | KIT (0.49) | KITHTR6GPR119GABRPGABRD | |
| SCHEMBL5001708 | 0.93 | HTR6 (0.53) | KITHTR6GPR119GRM1GRM5 | |
| SCHEMBL16035864 | 0.88 | KIT (0.46) | KITHTR6GPR119GABRPGABRD | |
| SCHEMBL23121219 | 0.88 | EGLN1 (0.39) | KIT | |
| SCHEMBL15586811 | 0.88 | KIT (0.39) | KITGPR119 | |
| SCHEMBL1356463 | 0.88 | KIT (0.46) | KITHTR6GPR119GABRPGABRD | |
| SCHEMBL16052496 | 0.88 | KIT (0.46) | KITHTR6GPR119GABRPGABRD | |
| SCHEMBL16036262 | 0.85 | KIT (0.46) | KITHTR6GPR119GABRPGABRD | |
| SCHEMBL16535994 | 0.83 | KIT (0.48) | KITHTR6GPR119GABRPGABRD | |
| SCHEMBL23139903 | 0.82 | GRM1 (0.42) | KITGPR119GABRPGABRDGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387602-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2022-12-08 | — | — | US | disclosed |
| US-20220387602-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2022-12-08 | — | — | US | disclosed |
| EP-4031247-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | Novartis AG (CH) | 2022-07-27 | — | — | EP | disclosed |
| WO-2021053495-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |
| WO-2021053495-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |
| US-9233983-B2 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2016-01-12 | — | — | US | disclosed |
| US-20150064196-A1 | Substituted Hetero-Bicyclic Compounds, Compositions and Medicinal Applications Thereof | IMPETIS BIOSCIENCES LIMITED (IN) | 2015-03-05 | — | — | US | disclosed |
| EP-2838898-A1 | SUBSTITUTED HETERO-BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | Advinus Therapeutics Limited (IN) | 2015-02-25 | — | — | EP | disclosed |
| WO-2013157022-A1 | SUBSTITUTED HETERO-BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LIMITED (IN) | 2013-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387602-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | JMJD7, MDM2, IDE | KIT 2948/4885HTR6 3501/4885GPR119 3689/4885 |
| US-20150064196-A1 | Substituted Hetero-Bicyclic Compounds, Compositions and Medicinal Applications Thereof | BTK, MALT1, LCK | KIT 510/4885HTR6 3069/4885GPR119 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.